The identifi cation of useful markers for early diagnosis of human colon cancer is a major goal still in progress. Clusterin is a pleiotropic protein with a broad range of functions. It has recently drawn much attention because of its association with cancer promotion and metastasis. It is involved in prosurvival and apoptosis processes that are carried out by two different isoforms. Secreted clusterin isoform (sCLU) is cytoprotective and its prosurvival function is the basis of the current phase I / II clinical trials against prostate, lung, and breast cancers. We have already shown that in colorectal cancer (CRC) there is an increased expression of sCLU. In this report, we investigated whether sCLU is released in the blood and stool of colon cancer patients in order to study sCLU as a potential diagnostic molecular marker for colon cancer screening.
INTRODUCTION
Colon cancer is currently the third most common cancer diagnosed among men and women and the second most common cause of death aft er lung cancer in the Western countries. A higher incidence of colon cancer is observed between the ages of 60 and 70, and 60 % of the patients survive up to 5 years (1) . Th e most important reason for the low percentage of recoveries is the fact that when the primary tumor is removed, a high number of patients have already developed micro-metastases, principally at the liver. Th erefore, methods for early screening are requested. At present, the early diagnosis protocols (secondary prevention) consist of rectal exploration, determination of fecal occult blood test and rectosigmoidoscopy periodically performed on individuals of 45 years of age, and on older and nonsymptomatic individuals. Periodic pan-colonoscopy is the only procedure for early diagnosis of Clusterin in Stool: A New Biomarker for Colon Cancer Screening ? neoplasia in individuals with positive familial history of colorectal cancer (CRC), in patients already having a neoplasia or aff ected by a syndrome with a high risk of neoplasia insurgence, who are part of the so-called " at-risk population " (2) . Randomized controlled trials have shown that annual or biennal screening in asymptomatic people over the age of 50 years using fecal occult blood tests can reduce CRC mortality by 15 -33 % . Nevertheless, fecal occult blood test, used for early diagnosis of colon carcinoma in clinical practice, yields frequent false-negative and false-positive results that lower the screening eff ectiveness and raise the program costs (3, 4) . On the basis of the above, new molecular pathogenetic markers that would overcome the restrictions of the invasive methods used at present, such as colonoscopy, are needed to improve the effi cacy, sensitivity, and specifi city of early diagnosis tests (5, 6) . Moreover, molecular markers specifi c for this pathology would help to stratify more selectively the cohort of patients really needing colonoscopy.
One of the signatures of a cancer cell is change in the nuclear and cytoplasmic structure and architecture. In particular, molecular changes in cell cycle or apoptosis-related protein expression and localization are associated with diff erent types of cancers. Recent studies have shown the increased expression of clusterin in cancer, suggesting a role of this protein in tumor progression (7, 8) .
Clusterin is a heterodimeric ( -and -chains) ubiquitous glycoprotein implicated in a large number of physiological processes and in the control of cellular proliferation. A number of isoforms have been characterized that diff er in the grade of glycosylation and in their function (9, 10) .
Several experimental data have shown a strong correlation between the presence of the diff erent isoforms of clusterin and tumoral progression (7) . Th e disappearance of the proapoptotic nuclear form (nCLU, 60 kDa) and the overexpression of the prosurvival secreted / cytoplasmatic isoform (sCLU, 40 kDa) marks the transition from normal cell to neoplastic phenotype. Besides, with the acquisition of aggressiveness, the disappearance of the proapoptotic CLU strongly associates with the loss of DNA repair activity of the complex Ku70 / 80 (11) and with the overexpression of the prosurvival-secreted form (sCLU). Th e expression of sCLU isoform directly correlates with tumor aggressiveness and with the metastatic potential of the tumor. It seems reasonable that the shift of CLU production can be related to exogenous factors such as interleukin-6 and transforming growth factorthat are present in the extracellular milieu of the tumoral mass (12) . Moreover, the increase of sCLU in tumors suggests that this isoform could be released in the extracellular space.
Th e results concerning the modulation of diff erent CLUs (proapoptotic nCLU and prosurvival sCLU) in the tumorigenesis of CRC suggest the possible role of sCLU as a potential new marker for the diagnosis and prognosis of CRC.
Th e use of clusterin as a diagnostic marker in some pathological conditions such as type II diabetes and several coronary pathologies has already been described (13) . Th ere were just a few earlier attempts to determine clusterin by enzyme-linked immunosorbent assay (ELISA) in tumoral pathologies, specifically in the blood of prostate carcinoma patients (14) . Moreover, clusterin level in the blood and urine has been shown to be a potential marker for bladder and kidney tumors, being directly related to the dimension of the neoplasia (15) .
In this report, we have highlighted that the appearance and progressive increase of the clusterin cytoplasmic isoform in tumors correlate with a signifi cant increase of clusterin in the serum and stool of patients aff ected by CRC. Furthermore, we confi rmed the positive correlation between the increasing serum clusterin level and tumor size, in human cancer xenograft in nude mice.
On the basis of these observations, we have currently also validated a new method for blood and stool immuno-dosage of clusterin in colon cancer patients by the use of specifi c oligoclonal antibodies, recognizing selectively the secreted isoform of clusterin.
METHODS

Case selection
Consecutive patients with suspected colon cancer undergoing gastrointestinal endoscopy, willing to participate in the study and providing written informed consent, were enrolled at the departments of general surgery of our institution. Th is being a feasibility and pilot study, the fi rst ever to test the diagnostic role of clusterin in patients with colon cancer, no formal sample size computation was performed, and the study sample was mainly chosen given the typical availability of pathologic specimens during the study period (1 year). Th e participants enrolled in the study are reported in Table 1 . None had preoperative chemotherapy or irradiation. Th e clinical and histopathogical features of the tumors selected for blood and stool studies are reported in Table 2 . Age-matched controls were enrolled at the Internal Medicine Clinics of our Institution, aft er confi rmation of lack of clinical history of neoplasia, CRC, systemic or bowel infl ammatory disease, and no diagnosis of diabetes or autoimmune pathologies. Th is study was approved by the local Ethics Committee.
Sample collection
Blood samples were obtained before surgery from patients with CRC and from no-CRC age-matched patients (controls), to determine the serum concentration of clusterin. Aft er clotting, the blood samples were centrifuged at 2500 r.p.m. for 15 min and the serum was removed, aliquoted, and stored at − 80 ° C until analysis.
Stool samples were obtained before surgery from patients with CRC and from no-CRC age-matched subjects (controls). Moreover, feces samples ( n = 10) were collected from autoptic examination (performed within 6 h from death), resulting in negative for any neoplasia and gastrointestinal diseases at the macroscopic evaluation of whole gastrointestinal apparatus, and were used as controls ( Table 1 ) . Stools were homogenized, and about 100 mg of each sample were suspended in stool extraction buff er by ScheBo Biotech AG (Giessen, Germany) at a concentration PATHOLOGY Clusterin in Stool for Colon Cancer Detection of 10 mg / ml. Th e protein extract was diluted 1:20 in phosphatebuff ered saline, and stored at − 80 ° C until analysis.
Morphological and Immunohistochemical studies
Hematoxylin and eosin sections were evaluated for the diagnosis and clinical staging of CRC (assessed according to the Dukes ' and TNM classifi cations).
Aft er a selection of the most signifi cant area of the neoplasia, a tissue microarray (TMA) was constructed including the cancer and normal mucosa of 50 CRC patients (28 tumors from the patients enrolled in the stool study, and 22 tumors from the archival paraffi n blocks). Tissue cores (1.2 mm diameter) were arrayed into the " host " paraffi n block using TMA CK3500 (BioRep, Milan, Italy). Th e TMA slides were incubated with the rabbit polyclonal antibody clusterin-(H-330) or the goat polyclonal antibody clusterin-(M-18) (Santa Cruz Biotechnology, Santa Cruz, CA). Specimens were also immunostained with the anti-Clu-C2 antibody produced by us (patent RM2004A000098), directed against the sCLU. Th e evaluation of the TMA immunohistochemistry staining was confi rmed by three independent observers unaware of the clinical data and molecular results (7) . Th e concordance between TMA and full sections was tested for all the antibodies in 10 specimens selected randomly.
Tissue staining was semiquantitatively graded for intensity from negative: 0 to strong (3 + + + ). Clusterin protein expression was deemed positive when weak ( + / − ) to strong ( + + + ) staining was present (12) .
Ex vivo cell culture and animal experimental model
Tumoral tissue and normal mucosa from the same patient were selected on hematoxylin and eosin frozen sections. Primary cell cultures were performed: 10 × 10 7 neoplastic and nonneoplastic colonic cells, ex vivo isolated, from tumoral and healthy colonic mucosa, were separately incubated in complete culture medium for 72 h at 37 ° C in a 5 % CO 2 humidifi ed incubator. Supernatants were stored at 4 ° C.
Human colon carcinoma (HTB-37, ATCC) Caco-2 cells were grown according to the condition suggested from ATCC. Caco-2 cells were subcutaneously injected in the right fl ank of six nude mice (10 × 10 6 Caco-2 cells / mouse). Before tumor cell injection, 500 l of blood were collected from each animal to determine the basal serum concentration of clusterin in mice. Mice were killed at days 15, 20, and 25 from tumor injection. At the killing of each mouse, blood was collected as described above and the tumor size determined. 
Enzyme-linked immunosorbent assay
A sandwich ELISA was performed as described earlier (13) , with the following modifi cations: the antibodies used were a mouse monoclonal antibody (anti-clusterin-chain, clone 41D, Upstate, NY) to coat the plates, a rabbit oligoclonal anti-sCLU antibody (C3) that we have produced (patent RM2004A000098), and a rabbit horseradish peroxidase-linked whole antibody (Amersham, GE Healthcare, UK) as primary and secondary antibodies. Th e C3 oligoclonal antibody was obtained by the selection of short antigenic epitopes specifi c for the sCLU isoform. Serum samples were diluted 1:8. Standard curves were generated with human recombinant clusterin (Alexis Biochemicals, San Diego, CA). A competitive ELISA kit (AdipoGen, Korea) for human clusterin was also used. Plates were read in an absorbance reader (Sunrise-Basic, Tecan, Switzerland).
Western blot and dot blot analysis
For western blot, 40 l of the stool extract of each sample was loaded on 12 % SDS-denaturing polyacrylamide gels. Dot blot analysis was performed using 3 l of serum or stool extracts denaturated in sample, and each sample was loaded on a polyvinyl-diene difl uoride membrane membrane. In both cases, the detection of clusterin was performed by the rabbit oligoclonal antibody anti-Clu-C2 produced by us (patent RM2004A000098). Standard curves were generated with human recombinant clusterin (Alexis Biochemicals).
Statistical analysis
All values provided in the text and fi gures are the mean of three independent experiments ± s.d. For immunohistochemical results, the statistical signifi cance was calculated by comparing the intensity values (from 0 to 3) between diff erent groups, e.g., CLU staining values in normal mucosae vs. adenocarcinomas (CRC). Unpaired t -tests were used for normally distributed continuous variables and Mann -Whitney U -tests were used for continuous variables not following a normal distribution (as shown by signifi cant results aft er Kolmogodorov -Smirnov tests). Calculations and upper and lower bounds for confi dence intervals (CI) were performed by nonparametric assay and SPSS soft ware (SPSS, Chicago, IL) (two tailed; P ≤ 0.05 was signifi cant).
Th e diagnostic performance of clusterin was appraised by means of receiver operating characteristic (ROC) curves, with corresponding area under the curve (AUC) (16) . In addition, the AUCs of ROCs from the stool and blood clusterin assay were compared according to Vergara et al. (17) Every case or control sample was measured three times for clusterin levels, and the averaged value was used for ROC curves. Th e ROC curves provided several cutoff points to show the trade-off between sensitivity and specifi city at diff erent cutoff values. Sensitivity and specifi city values were calculated with confi dence interval analysis according to the Wilson method.
RESULTS
sClusterin is overexpressed in colon cancer
Expression of CLU (nCLU and sCLU isoforms) was analyzed by immunohistochemistry in human colon cancer tissues ( n = 50) and in normal mucosa aside from the neoplasia ( n = 50). Participants enrolled in this study, and their clinical and histopathological features are reported in Table 1 and Table 2 . CLU immunostaining was performed with anti-CLU C2 that we produced and confi rmed by the use of commercial antibodies as described earlier (7, 12) . CLU was expressed quite exclusively in the nuclei of normal mucosa, whereas nuclear CLU staining was not detected in all carcinomas observed. On the other hand, cytoplasmic CLU expression, faintly present in normal mucosa, was strongly expressed in all colon carcinomas (normal mucosae vs. carcinomas: P = 0.02) ( Figure 1 ) and its upregulation correlated with the node status (any T, N0 vs. any T, N1: P = 0.04). To defi ne whether the overexpression of sCLU in the cytoplasm of tumors was correlated with an increased extracellular release, tumoral cells and normal mucosa were aseptically isolated from surgical biopsies and incubated for 72 h. Culture supernatant from the ex vivo -isolated cells of healthy and neoplastic colonic mucosa was collected and the clusterin level was evaluated by ELISA. A signifi cant increase of the clusterin level (2.9 times, P = 0.03) was found in the culture supernatant of tumoral cells, compared with healthy mucosa cells of the same patient ( Figure 2a ).
Serum clusterin level correlates with tumor size in a tumor xenograft model
To investigate whether clusterin release from colon cancer cells could eff ectively aff ect the total amount of circulating protein in blood, 10 × 10 6 human colon cancer cells, Caco-2, were underskin injected in nude mice ( n = 6) aft er blood was drawn for CLU endogenous basal level determination. To evaluate the CLU level in relation to tumor size, mice were killed at days 15 ( n = 2), 20 ( n = 2), and 25 ( n = 2) aft er tumor injection. As shown in Figure 2b , the level of clusterin, evaluated by dot blot analysis, was signifi cantly increased in the blood of tumor-bearing mice, compared with uninjected mice. Data showed that tumor cells are able to release clusterin and that the increasing level of clusterin in the blood of tumor-bearing mice as compared with tumor-free mice, evaluated in diff erent times of tumor growth, is exclusively related to tumor presence. Moreover, the rise of clusterin serum levels was related to the tumor volume increase ( Figure 2b ).
Clusterin level in blood increases in colon cancer patients
Th e quantitative determination of sCLU in biological fl uids (blood and stool) was developed by adapting the ELISA technique described earlier (13) . A sandwich ELISA was performed using a rabbit oligoclonal antibody raised against the secreted glycosylated isoform of human clusterin, anti-CLU C3, that we have produced and with a commercial antibody. Th e results obtained were confi rmed by commercial ELISA, as described in the Methods section. As shown in Figure 3a , clusterin levels did not signifi cantly diff er in sera between cancer patients and healthy individuals ( P = 0.07 Student ' s t -test). Moreover, the reproducibility of the results was strongly infl uenced by the clustering properties of this stress-folding
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Clusterin level in stool increases in cancer patients
To avoid the interference of the increased level of clusterin in blood owing to other not tumoral or tumoral diseases (cancer of the breast, prostate, testicle, ovary, central nervous system, hemolymphopoietic system), the level of clusterin was determined in the stool of the CRC patients. Clusterin determination was performed both by commercial and by oligoclonal antibodies. A preliminary observation on the integrity of the protein in stool was performed by western blot ( Figure 4a ). Dot blot analysis of fecal extracts from cancer patients ( n = 28) compared with controls ( n = 25), provided signifi cant diff erences with mean values of 47.5 ± 19.6 and 26.8 ± 12.8 g / g, respectively (CRC vs. controls: P < 0.000) ( Figure 4b ). Th e analysis was performed three times in triplicate. Moreover, the analysis in patients ( n = 16) undergone to protein, as reported earlier. In fact, clusterin determination depends strongly on the protein -protein binding, pH, and temperature (13) .
Th erefore, the same samples were also analyzed by dot blot. Th is technique, based on the immobilization of the sample on a poly-vinyl-diene difl uoride membrane, was chosen to avoid the hydrophobic regions of clusterin to contact the hydrophobic regions of other proteins (or other molecules of clusterin) and form " clusters " that could precipitate and be washed away. Th e dot blot analysis ( Figure 3b ) on human sera from CRC patients (CRC, n = 35) and no cancerous individuals (controls, n = 25) displayed statistically signifi cant diff erences in the clusterin levels. In fact, clusterin concentration was 82.8 ± 26.9 g / ml in CRC cancer patients and 57.8 ± 19.3 g / ml in controls (CRC vs. controls: P = 0.0002). endoscopic polipeptomy showed no signifi cant diff erences in sCLU level between low-grade dysplasia adenomas and control samples ( P = 0.170) and between high-grade adenomas and CRC samples ( P = 0.065). Conversely, the two groups of dysplastic lesion, i.e., low-and high-grade dysplasia adenomas, showed signifi cant diff erences in the levels of sCLU ( P = 0.003). Th ese data confi rmed the observations that we have published earlier, where only the high-grade dysplasia adenomas (advanced adenomas) and CRC tissues displayed an overexpression of sCLU isoform (7) . Also, a signifi cant correlation between clusterin values in stool and stage of cancer disease was found ( P = 0.05).
We also constructed ROC curves by plotting sensitivity (the proportion of true-positive results) vs. 1-specifi city (the proportion of false-positive results) both in sera and in stool ( Figure 5 ) and determined the corresponding AUC to show the ability of secreted clusterin to discriminate nonneoplastic (controls) from neoplastic lesions (CRC). Th e AUC is a useful onestatistic summary of the diagnostic accuracy of the assay. Both the tests showed a moderate diagnostic accuracy, AUC being in the interval 0.7 -0.9 (16) .
Th e AUCs of ROCs from stool and blood clusterin were analytically compared (17) , and nonsignifi cant diff erences were found between the two methods ( P = 0.686), despite the AUC from stool assay being 0.81 (95 % CI 0.695 -0.926), whereas in blood it was 0.77 (95 % CI 0.641 -0.901). Th e ROC curves also provided several cutoff points to show the tradeoff between sensitivity and specifi city at diff erent cutoff values. For dot blot assay in blood, the optimal threshold was 88.5 g / ml corresponding to 55.6 % (95 % CI 39.7 -69.9) sensitivity and 100 % (95 % CI 85.1 -100) specifi city, whereas the stool test reached 66.7 % (95 % CI 47.8 -81.4) sensitivity and 84 % (95 % CI 65.3 -93.6) specifi city at the selected cutoff value of 34.6 g / g ( Table 3 ). 
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DISCUSSION
Th e early diagnosis and disease recurrence of CRC are central to the eff ective treatment of this pathology. In addition, molecular markers indicative for the disease relapse or micrometastasis expansion actually are poorly available. In the current report, we showed for the fi rst time that in colon cancer the upregulated cytoplasmic CLU is extracellularly released both in blood and in stool. By developing a sensitive method, we found a signifi cant increase of clusterin both in the blood and stool of cancer-aff ected patients, highlighting its potential value as a new diagnostic biomarker for a noninvasive test for colon cancer screening.
Th ere is a consensus that CRC screening is eff ective to prevent this disease in many cases (6) . Owing to CRC screening, the incidence of this tumor has dropped in recent years. Th ere is less consensus regarding optimal screening strategies, as sensitivity, specifi city, and patient acceptance limit current options. To overcome these barriers, a range of approaches, including proteomics-based testing, stool genetic testing, radiological imaging, and enhanced endoscopies, have been the focus of intense research (1, 3, 4, 18, 19) . A useful diagnostic assay must be sensitive, must detect cancer at the onset, and must have a high specifi city to minimize false positives that necessitate expensive and invasive examination. Stool testing, unlike other conventional screening approaches, is noninvasive and requires no cathartic preparation. However, widely used fecal occult blood test yields frequent false-negative and false-positive results that lower screening eff ectiveness and raise program costs. According to literature, overall new stool tests for CRC diagnosis have a higher sensitivity, whereas specifi city is still to be defi ned. In particular, specifi cities of about 95 % have been reported for tests based on the detection of genetic mutations occurring in the tumoral tissues, but not in the early stage, and these are not present in all cases. On the other hand, markers such as calprotectin may represent both a marker of cancer disease and of bowel infl ammation, leading to nearly 30 % false-positive results (20, 21) . Recently, a high-specifi c serum testing for colon cancerspecifi c antigen 2 and 4 has been proposed, but the limitation of this test is that not all colon cancers may express the nuclear matrix protein colon cancer-specifi c antigen 2 and 4 (20 -30 % ) and therefore a multiple marker testing is needed (22) .
We have demonstrated earlier a tumor-related pattern shift of CLUs production in colon tumorigenesis observing that sCLU was upregulated in the cytoplasm of neoplastic cells and correlated with the stage of the disease (8) . In fact, clusterin is expressed in the nucleus and weakly expressed in the cytoplasm of normal colonocytes, in particular in the luminal crypt side. Conversely, CLU was found elevated in the cytoplasm of colon carcinomas (50 out of 50 observed) and its production was shown to correlate with the nodal status. Th e dot blot assay for CLU detection in stool shows diagnostic accuracy with satisfactory values of sensitivity and specifi city, compared with the other noninvasive cancer screening tests widely used. Our preliminary observations obtained by stool analysis clearly point out that the increase of CLU in cancer patients is signifi cant not only compared with healthy individuals, but also compared with patients aff ected by systemic or bowel infl ammatory pathologies and benign lesions of the colon. Preliminary data obtained from the analysis of adenomas with low-grade dysplasia, endoscopically removed and histologically characterized, showed no signifi cant diff erences in sCLU level in stool compared with that of healthy individuals. From an examination of the stool samples, it is ruled out that in a healthy population clusterin is not normally present in high amounts as a discarding product and could constitute a point-matched control to cross with blood clusterin level. Data obtained by the determination of clusterin in blood by dot blot test showed a 56 % sensitivity calculated by the ROC curve and, considering the entire study population, a 100 % specifi city. However, the high specifi city based on the blood CLU level could be due to the cases selection that did not include individuals with infl ammatory pathologies, diabetes, autoimmune diseases, and cardiocirculatory pathologies reported earlier to present high CLU levels in serum (13) . More clinical cases could be helpful to defi ne the clinical relevance of CLU level in the stool and blood of individuals aff ected by infl ammatory pathologies, with respect to CRC patients. Moreover, a signifi cant increase of sCLU in stool was evidenced not only in CRC patients but also in individuals aff ected by high-grade adenomas, suggesting that clusterin could represent a useful biomarker to detect cancer at a preventable stage in neoplastic precursor lesions. It is worthy of note that a significant decrease of CLU level was found in a small cohort of follow-up patients ( n = 8) 6 -8 months aft er tumor removal (data not shown), indicating its potential role as a progression-free survival marker.
Overall, these data propose sCLU as a new marker of onset, prognosis, and relapse of colon cancer. Large trials with full clinical data and follow-up available on the sCLU detection in stool will need to confi rm its potential value for noninvasive, eff ective, and low-cost screening programs for CRC detection. Moreover, studies on the molecular mechanisms that regulate the activation of clusterin promoter and its isoforms shift ing could provide new molecular targets for specifi c anti-neoplastic therapies. ACC, maximal accuracy; AUC, area under the ROC curve; fp, false-positive rate (1 -specifi city) at OT; N, number of negative instances; OT, optimal threshold; P, number of positive instances; tp, true-positive rate (sensitivity) at OT.
